Enterprise Therapeutics: Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

(marketscreener.com) ETD001 is a novel inhaled, long-acting ENaC inhibitor Therapy applicable to all cystic fibrosis patients, independent of genotypehttps://www.marketscreener.com/news/latest/Enterprise-Therapeutics-doses-first-subjects-in-Phase-I-trial-for-novel-cystic-fibrosis-therapy-ETD0--35596794/?utm_medium=RSS&utm_content=20210614